Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020206137 - CDK2/5 DEGRADERS AND USES THEREOF

Publication Number WO/2020/206137
Publication Date 08.10.2020
International Application No. PCT/US2020/026411
International Filing Date 02.04.2020
IPC
C07D 401/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
A61K 31/45 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
45having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
A61K 31/506 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 47/54 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
Applicants
  • DANA-FARBER CANCER INSTITUTE, INC. [US]/[US]
  • GRAY, Nathanael [US]/[US]
  • KWIATKOWSKI, Nicholas [US]/[US]
  • FISCHER, Eric [US]/[US]
  • DONOVAN, Katherine [US]/[US]
Inventors
  • GRAY, Nathanael
  • KWIATKOWSKI, Nicholas
  • FISCHER, Eric
  • DONOVAN, Katherine
  • ZHANG, Tinghu
  • TENG, Mingxing
  • JIANG, Jie
Agents
  • CLARKE, J. D.
  • PYSHER, Paul
  • CHACLAS, George N.
  • COHEN, Jerry
  • EMMONS, Richard B.
  • COWLES, Christopher R.
  • GOLDMAN, Gabriel
  • JOBSE, Bruce D.
  • MARAIA, Joseph M.
  • MCGRATH, Daniel
  • MILLS, Steven
  • MOORE, Ronda P.
  • QUINN, Joseph P.
  • SCHEPPER, Marlo M.
  • SERIO, John C.
  • SORKIN, Paul D.
  • SUSAN, Janine M.
  • FOLEY, Shawn
  • SCHULTZ, Christopher S.
  • KARIMI, Pegah
Priority Data
62/829,30204.04.2019US
62/981,33425.02.2020US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CDK2/5 DEGRADERS AND USES THEREOF
(FR) AGENTS DE DÉGRADATION DE CDK2/5 ET UTILISATIONS ASSOCIÉES
Abstract
(EN)
The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by dysfunctional cyclin-dependent kinase 2 (CDK2) and CDK5 activity.
(FR)
La présente invention concerne des composés bifonctionnels, des compositions et des méthodes de traitement de maladies ou d'affections à médiation par la kinase 2 dépendante de la cycline (CDK2) dysfonctionnelle et une activité de CDK5.
Latest bibliographic data on file with the International Bureau